Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

by Zacks Equity Research

The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

    Regeneron and Sanofi Get Favorable Ruling Against Amgen

    by Zacks Equity Research

    Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.

      ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status

      by Zacks Equity Research

      ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.

        Ligand (LGND) Signs Deal to Acquire Crystal Bioscience

        by Zacks Equity Research

        Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.

          Celsion's Immunotherapy Candidate Impresses, Stock Surges

          by Zacks Equity Research

          Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

            Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up

            by Zacks Equity Research

            Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.

              Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy

              by Zacks Equity Research

              Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.

                FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

                by Zacks Equity Research

                Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

                  Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

                  by Zacks Equity Research

                  Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

                    Lilly (LLY) Makes Leadership Changes to Executive Positions

                    by Zacks Equity Research

                    Eli Lilly and Company (LLY) makes some executive appointments for various departments.

                      Prothena's Psoriasis Candidate Disappoints in Phase I Study

                      by Zacks Equity Research

                      Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

                        Radius (RDUS) Enrols First Patient in Breast Cancer Study

                        by Zacks Equity Research

                        Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.

                          Allergan Authorizes New $2B Share Buyback Plan, Stock Up

                          by Zacks Equity Research

                          Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.

                            Juno Tenders $250M Follow-on Public Offering of Common Stock

                            by Zacks Equity Research

                            Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.

                              Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

                              by Zacks Equity Research

                              GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.

                                Supernus Drops SPN-810's Lower Dose Test in Phase III Trials

                                by Zacks Equity Research

                                Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.

                                  Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

                                  by Zacks Equity Research

                                  The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.

                                    Novartis Announces Positive Data on Urticaria Drug Xolair

                                    by Zacks Equity Research

                                    Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.

                                      BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

                                      by Zacks Equity Research

                                      The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

                                        GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

                                        by Zacks Equity Research

                                        GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

                                          Alexion (ALXN) Reports Interim Results for Soliris Study

                                          by Zacks Equity Research

                                          Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory generalized myasthenia gravis.

                                            Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

                                            by Zacks Equity Research

                                            Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

                                              Roche (RHHBY) Announces Data on Respiratory Drug Esbriet

                                              by Zacks Equity Research

                                              Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.

                                                Alexion to Restructure Operations, to Lower Headcount by 20%

                                                by Zacks Equity Research

                                                Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.

                                                  Teva's Leukemia Drug sNDA Granted Priority Review by the FDA

                                                  by Zacks Equity Research

                                                  Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.